

**Measure #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias:
Baseline Cytogenetic Testing Performed on Bone Marrow – National Quality Strategy Domain:
Effective Clinical Care**

2017 OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

MEASURE TYPE:
Process

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia who had baseline cytogenetic testing performed on bone marrow

INSTRUCTIONS:
This measure is to be reported a minimum of **once per performance period** for all myelodysplastic syndrome (MDS) and Acute Leukemia patients seen during the **performance period**, regardless of when MDS or Acute Leukemia diagnosis was made; the quality action being measured is that baseline cytogenetic testing on bone marrow was performed for each patient with MDS and Acute Leukemia at the time of diagnosis or prior to initiating treatment. It is anticipated that eligible clinicians who provide services for patients with the diagnosis of myelodysplastic syndromes or an acute leukemia (not in remission) will submit this measure.

Measure Reporting:

The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Diagnosis for MDS or acute leukemia – not in remission (ICD-10-CM): C91.00, C91.02, C92.00, C92.02, C92.40, C92.42, C92.50, C92.52, C92.60, C92.62, C92.A0, C92.A2, C93.00, C93.02, C94.00, C94.02, C94.20, C94.22, C95.00, C95.02, D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.A, D46.B, D46.C, D46.Z

AND

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

WITHOUT

Telehealth Modifier: GQ, GT

NUMERATOR:
Patients who had baseline cytogenetic testing performed on bone marrow

Definition:

Baseline Cytogenetic Testing – Testing that is performed at time of diagnosis or prior to initiating treatment (transfusion, growth factors, or antineoplastic therapy) for that diagnosis

Numerator Options:

Performance Met:

Cytogenetic testing performed on bone marrow at time of diagnosis or prior to initiating treatment (3155F)

OR

Denominator Exception:

Documentation of medical reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, no liquid bone marrow or fibrotic marrow) **(3155F with 1P)**

OR

Denominator Exception:

Documentation of patient reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, at time of diagnosis receiving palliative care or not receiving treatment as defined above) **(3155F with 2P)**

OR

Denominator Exception:

Documentation of system reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, patient previously treated by another physician at the time cytogenetic testing performed) **(3155F with 3P)**

OR

Performance Not Met:

Cytogenetic testing not performed on bone marrow at time of diagnosis or prior to initiating treatment, reason not otherwise specified **(3155F with 8P)**

RATIONALE:

For MDS:

Cytogenetic testing is an integral component in calculating the International Prognostic Scoring System (IPSS) score. Cytogenetic testing should be performed on the bone marrow of patients with MDS in order to guide treatment options, determine prognosis, and predict the likelihood of disease evolution to leukemia.

For acute leukemias:

In addition to establishing the type of acute leukemia, cytogenetic testing is essential to detect chromosomal abnormalities that have diagnostic, prognostic, and therapeutic significance. Performing cytogenetic analysis on patients with AML identifies a subgroup of patients where further molecular genetics testing is indicated.

CLINICAL RECOMMENDATION STATEMENTS:

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines:

For MDS:

Bone marrow aspiration with Prussian blue stain for iron and biopsy are needed to evaluate the degree of hematopoietic cell maturation abnormalities and relative proportions, percentage of marrow blasts, marrow cellularity, presence or absence of ringed sideroblasts (and presence of iron per se), and fibrosis. Cytogenetics for bone marrow samples (by standard karyotyping methods) should be obtained because they are of major importance for prognosis. (Category 2A Recommendation) (NCCN MDS, 2016)

Significant independent variables for determining outcome for both survival and AML evolution were found to be marrow blast percentage, number of cytopenias, and cytogenetic subgroup (good, intermediate, poor). The percentage of marrow blasts was divisible into four categories: 1) less than 5%, 2) 5% to 10%, 3) 11% to 20%, and 4) 21% to 30% (Category 2A). (NCCN MDS, 2016)

Acute Lymphoblastic Leukemia:

Hematopathology evaluations should include morphologic examination of malignant lymphocytes using Wright- Giemsa-stained slides and hematoxylin and eosin (H&E)-stained core biopsy and clot sections, comprehensive immunophenotyping with flow cytometry, and assessment of cytogenetic or molecular abnormalities. Identification of specific recurrent genetic abnormalities is critical for disease evaluation, optimal risk stratification, and treatment planning. (Category 2A Recommendation) (NCCN, 2015)

Acute Myeloid Leukemia:

Although cytogenetic information is usually unknown when treatment is initiated in patients with de novo AML, karyotype represents the single most important prognostic factor for predicting remission rate, relapse, and overall survival. Therefore, the importance of obtaining sufficient samples of marrow or peripheral blood blasts at diagnosis for this analysis cannot be overemphasized (Category 2A Recommendation). (NCCN AML, 2016)

The importance of obtaining adequate samples on marrow or peripheral blood at diagnosis to do full karyotyping as well as FISH probes for the most common abnormalities cannot be overemphasized. In addition to basic cytogenetic analysis, new molecular markers are helping to refine prognostics groups particularly in patients with a normal karyotype. (Category 2A Recommendation) (NCCN AML, 2016)

COPYRIGHT:

The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the PCPI® Foundation (PCPI®) or American Society of Hematology (ASH). Neither ASH, nor the American Medical Association (AMA), nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.

The AMA's and AMA-PCPI's significant past efforts and contributions to the development and updating of the Measures is acknowledged. ASH is solely responsible for the review and enhancement ("Maintenance") of the Measures as of August 15, 2014.

ASH encourages use of the Measures by other health care professionals, where appropriate.


THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2016 PCPI® Foundation and American Society of Hematology. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2016 American Medical Association. LOINC® copyright 2004-2016 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2016 The International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2016 World Health Organization. All Rights Reserved.

2017 Registry Individual Measure Flow
#67 NQF #0377: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline
Cytogenetic Testing Performed on Bone Marrow



SAMPLE CALCULATIONS:

Data Completeness=

Performance Met (a=4 patients) + Denominator Exception (b¹+b²+b³=1 patient) + Performance Not Met (c=2 patients) = 7 patients = 87.50%
 Eligible Population / Denominator (d=8 patients) = 8 patients

Performance Rate=

Performance Met (a=4 patients) = 4 patients = 66.67%
 Data Completeness Numerator (7 patients) – Denominator Exception (b¹+b²+b³=1 patient) = 6 patients

*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency- Patient-Process

CPT only copyright 2016 American Medical Association. All rights reserved.
 The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v1

2017 Registry Individual Measure Flow
#67 NQF #0377: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline
Cytogenetic Testing Performed on Bone Marrow

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator
2. Check Patient Age:
 - a. If Patient Age is greater than or equal to 18 Years of age at Date of Service equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
 - b. If Patient Age is greater than or equal to 18 Years of age at Date of Service equals Yes during the measurement period, proceed to check Patient Diagnosis.
3. Check Patient Diagnosis:
 - a. If Diagnosis of MDS or Acute Leukemia (Not in Remission) as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Diagnosis of MDS or Acute Leukemia (Not in Remission) as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
4. Check Encounter Performed:
 - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.
5. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing.
 - b. If Telehealth Modifier equals No, include in the Eligible population.
6. Denominator Population:
 - a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 episodes in the sample calculation.
7. Start Numerator
8. Check Cytogenetic Testing Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment:
 - a. If Cytogenetic Testing Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 patients in Sample Calculation.

- c. If Cytogenetic Testing Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment equals No, proceed to Documentation of Medical Reason(s) for Not Performing Baseline Cytogenetic Testing on Bone Marrow.
- 9. Check Documentation of Medical Reason(s) for Not Performing Baseline Cytogenetic Testing on Bone Marrow:
 - a. If Documentation of Medical Reason(s) for Not Performing Baseline Cytogenetic Testing on Bone Marrow equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b1 equals 1 patient in the Sample Calculation.
 - c. If Documentation of Medical Reason(s) for Not Performing Baseline Cytogenetic Testing on Bone Marrow equals No, proceed to Documentation of Patient Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow.
- 10. Check Documentation of Patient Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow:
 - a. If Documentation of Patient Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b2 equals 0 patients in the Sample Calculation.
 - c. If Documentation of Patient Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow equals No, proceed to Documentation of System Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow.
- 11. Check Documentation of System Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow:
 - a. If Documentation of System Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter b3 equals 0 patients in the Sample Calculation.
 - c. If Documentation of System Reason(s) for not Performing Baseline Cytogenetic Testing on Bone Marrow equals No, proceed to Cytogenetic Testing Not Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified.
- 12. Check Cytogenetic Testing Not Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified:
 - a. If Cytogenetic Testing Not Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified equals Yes, include in Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 2 patients in the Sample Calculation.
 - c. If Cytogenetic Testing Not Performed on Bone Marrow at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified equals No, proceed to Data Completeness Not Met .

13. Check Data Completeness Not Met :

- a. If Data Completeness Not Met, the Quality Data Code or equivalent was not reported. 1 patient has been subtracted from the data completeness numerator in sample calculation.

SAMPLE CALCULATIONS:

Data Completeness=

$$\frac{\text{Performance Met (a=4 patients) + Denominator Exception (b}^1\text{+b}^2\text{+ b}^3\text{=1 patient) + Performance Not Met (c=2 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{7 \text{ patients}}{8 \text{ patients}} = 87.50\%$$

Performance Rate=

$$\frac{\text{Performance Met (a=4 patients)}}{\text{Data Completeness Numerator (7 patients) – Denominator Exception (b}^1\text{+b}^2\text{+ b}^3\text{=1 patient)}} = \frac{4 \text{ patients}}{6 \text{ patients}} = 66.67\%$$